Sanofi
SNYNFOTCHealthcare● Active
$88.31
+$0.60(+0.68%)
Market Cap$106.2B
P/E Ratio—
52W High$106.34
52W Low$83.17
Sanofi (SNYNF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SNYNF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 23, 2026EPS Actual
$1.54
Revenue
$12.94B
Est. $12.87B · +0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 23, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
SNYNF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 23, 2026 | — | $1.54 | — | $12.94B | $12.87B | +0.5% |
| ▲ Q1 FY2026 | Jan 29, 2026 | $1.65 | $1.95 | +18.2% | $27.87B | $11.71B | +137.9% |
| — Q3 FY2025 | Jul 31, 2025 | — | $3.76 | — | $12.64B | $12.36B | +2.3% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $1.69 | $1.79 | +5.9% | $11.63B | $10.00B | +16.3% |
| ▼ Q1 FY2025 | Jan 30, 2025 | $1.69 | $1.31 | -22.5% | $7.90B | $9.51B | -16.9% |
| ▲ Q4 FY2024 | Oct 25, 2024 | $2.48 | $2.86 | +15.3% | $15.53B | $13.89B | +11.8% |
| ▲ Q3 FY2024 | Jul 25, 2024 | $1.67 | $1.73 | +3.6% | $22.80B | $12.77B | +78.6% |
| ▲ Q2 FY2024 | Apr 25, 2024 | $1.73 | $1.78 | +2.9% | $11.94B | — | — |
Q2 FY2026
Apr 23, 2026
EPS Actual
$1.54
EPS Est.
—
EPS Surpr.
—
Revenue
$12.94B
Q1 FY2026
Jan 29, 2026Beat
EPS Actual
$1.95
EPS Est.
$1.65
EPS Surpr.
+18.2%
Revenue
$27.87B
Q3 FY2025
Jul 31, 2025
EPS Actual
$3.76
EPS Est.
—
EPS Surpr.
—
Revenue
$12.64B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$1.79
EPS Est.
$1.69
EPS Surpr.
+5.9%
Revenue
$11.63B
Q1 FY2025
Jan 30, 2025Miss
EPS Actual
$1.31
EPS Est.
$1.69
EPS Surpr.
-22.5%
Revenue
$7.90B
Q4 FY2024
Oct 25, 2024Beat
EPS Actual
$2.86
EPS Est.
$2.48
EPS Surpr.
+15.3%
Revenue
$15.53B
Q3 FY2024
Jul 25, 2024Beat
EPS Actual
$1.73
EPS Est.
$1.67
EPS Surpr.
+3.6%
Revenue
$22.80B
Q2 FY2024
Apr 25, 2024Beat
EPS Actual
$1.78
EPS Est.
$1.73
EPS Surpr.
+2.9%
Revenue
$11.94B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $1.37 | $1.41 | $1.47 | 1 |
| Q3 FY2025 | $2.61 | $2.67 | $2.81 | 1 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $11.5B | $11.7B | $12.0B | 4 |
| Q2 FY2026 | $9.3B | $9.6B | $10.1B | 4 |
| Q1 FY2026 | $8.8B | $8.9B | $9.0B | 5 |
| Q4 FY2025 | $9.8B | $9.9B | $10.0B | 7 |
| Q3 FY2025 | $10.5B | $10.9B | $11.5B | 6 |
| Q2 FY2025 | $8.2B | $8.5B | $9.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 23, 2026 | — | $92.44 | $92.44 | +0.00% |
| ▲ Q1 FY2026 | Jan 29, 2026 | +18.2% | $90.59 | $91.11 | +0.57% |
| — Q3 FY2025 | Jul 31, 2025 | — | $97.77 | $92.60 | -5.29% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +5.9% | $106.45 | $106.45 | +0.00% |
| ▼ Q1 FY2025 | Jan 30, 2025 | -22.5% | $105.85 | $108.00 | +2.03% |
| ▲ Q4 FY2024 | Oct 25, 2024 | +15.3% | $102.35 | $102.35 | +0.00% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +3.6% | $98.87 | $105.61 | +6.82% |
| ▲ Q2 FY2024 | Apr 25, 2024 | +2.9% | $94.00 | $95.54 | +1.64% |
Q2 FY2026+0.00%
Report Date
Apr 23, 2026
EPS Beat/Miss
—
Price Before
$92.44
Price After
$92.44
Q1 FY2026+0.57%
Report Date
Jan 29, 2026
EPS Beat/Miss
+18.2%
Price Before
$90.59
Price After
$91.11
Q3 FY2025-5.29%
Report Date
Jul 31, 2025
EPS Beat/Miss
—
Price Before
$97.77
Price After
$92.60
Q2 FY2025+0.00%
Report Date
Apr 24, 2025
EPS Beat/Miss
+5.9%
Price Before
$106.45
Price After
$106.45
Q1 FY2025+2.03%
Report Date
Jan 30, 2025
EPS Beat/Miss
-22.5%
Price Before
$105.85
Price After
$108.00
Q4 FY2024+0.00%
Report Date
Oct 25, 2024
EPS Beat/Miss
+15.3%
Price Before
$102.35
Price After
$102.35
Q3 FY2024+6.82%
Report Date
Jul 25, 2024
EPS Beat/Miss
+3.6%
Price Before
$98.87
Price After
$105.61
Q2 FY2024+1.64%
Report Date
Apr 25, 2024
EPS Beat/Miss
+2.9%
Price Before
$94.00
Price After
$95.54
Avg Beat Reaction+1.81%
Avg Miss Reaction+2.03%
Beat Rate5 / 8 quarters
Largest Move+6.82% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SNYNF ends December
Sanofi (SNYNF) most recently reported earnings on April 23, 2026 for Q2 FY2026, posting EPS of $1.54 (in line with the analyst consensus of —). SNYNF has beaten EPS estimates for 2 consecutive quarters. The next SNYNF earnings date is expected around September 1, 2026.
Each quarter, investors track SNYNF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SNYNF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SNYNF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SNYNF earnings · 4 questionsSanofi's next earnings report is expected around September 1, 2026. SNYNF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SNYNF historically reports after market close (AMC).
SNYNF earnings datewhen is SNYNF earningsSNYNF next earnings datewhen does SNYNF report earningsSNYNF earnings calendar
▸ Source: FMP · Sanofi SEC filings · US GAAP · Sanofi SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026